Novo Nordisk (Ozempic)
Acquired
Navigating the Complexities of GLP-1 Drugs and Insulin Market Dynamics
This chapter explores the emergence of GLP-1 medications and the challenges patients face regarding accessibility and cost, resulting in issues with adherence. It discusses the evolving insulin market, particularly the competition between major companies and the impact of new biosimilars and pricing strategies. The conversation also examines the intricacies of pharmaceutical patents, market positioning, and the societal attitudes towards drugs like Ozempic.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
